The DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Generative artificial intelligence empowers digital twins in drug discovery and clinical trials
Open accessAbstract
INTRODUCTION: The concept of Digital Twins (DTs) translated to drug development and clinical trials describes virtual representations of systems of various complexities, ranging from individual cells to entire humans, and enables in silico simulations and experiments. DTs increase the efficiency of drug discovery and development by digitalizing processes associated with high economic, ethical, or social burden. The impact is multifaceted: DT models sharpen disease understanding, support biomarker discovery and accelerate drug development, thus advancing precision medicine. One way to realize DTs is by generative artificial intelligence (AI), a cutting-edge technology that enables the creation of novel, realistic and complex data with desired properties. AREAS COVERED: The authors provide a brief introduction to generative AI and describe how it facilitates the modeling of DTs. In addition, they compare existing implementations of generative AI for DTs in drug discovery and clinical trials. Finally, they discuss technical and regulatory challenges that should be addressed before DTs can transform drug discovery and clinical trials. EXPERT OPINION: The current state of DTs in drug discovery and clinical trials does not exploit the entire power of generative AI yet and is limited to simulation of a small number of characteristics. Nonetheless, generative AI has the potential to transform the field by leveraging recent developments in deep learning and customizing models for the needs of scientists, physicians and patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures








Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the healthcare domain, medical AI and ML models have demonstrated the potential to improve patient outcomes, reduce cost burdens, accelerate clinical trials, and revolutionize the way we diagnose, treat, and prevent disease [26,28–31].”
From Bias in medical AI: Implications for clinical decision-making (2024) · cites this paper as [29]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“because synthetic data are similar to but not the same as real data, they can be used to eliminate or mask personal identifiers and protect the confidentiality of human participants [31, 81, 200].”
From The ethics of using artificial intelligence in scientific research: new guidance needed for a new tool (2025) · cites this paper as [31]
Experimental — accuracy not yet measuredIn the citing paper
“Already, AI is employed in clinical trials to accelerate enrollment, monitor patients (e.g., wearables), and improve retention [29,114,115].”
From Bias in medical AI: Implications for clinical decision-making (2024) · cites this paper as [29]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
LeCun, Y., Bengio, Y., & Hinton, G. (2015) · Nature · doi:10.1038/nature14539 · Cited by 84,126
Multimodal Machine Learning: A Survey and Taxonomy
Baltrusaitis, T., Ahuja, C., & Morency, L.-P. (2019) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2018.2798607 · Cited by 5,018
The Principles of Humane Experimental Technique
(1960) · Medical Journal of Australia · doi:10.5694/j.1326-5377.1960.tb73127.x · Cited by 4,912 · cited 1×
“DTs of animal models enable animal alternative testing solutions, i.e. increased animal welfare, by the replacement, reduction and refinement (3Rs) principle [53].”
BackgroundOn the Opportunities and Risks of Foundation Models
Bommasani, R., Hudson, D. A., Adeli, E., Altman, R., Arora, S., von Arx, S., Bernstein, M. S., Bohg, J., Bosselut, A., Brunskill, E., et al. (2021) · arXiv · doi:10.48550/arxiv.2108.07258 · Cited by 2,676 · cited 1×
“Another possible technological advance would be a foundation model [64]that is able to scale across all preclinical and clinical DTs, from cell to humans, and be adapted to specific use cases.”
BackgroundFundamentals of Clinical Trials
Friedman, L. M., Furberg, C. D., DeMets, D. L., Reboussin, D. M., & Granger, C. B. (2015) · doi:10.1007/978-3-319-18539-2 · Cited by 2,237
Diffusion Models in Vision: A Survey
Croitoru, F.-A., Hondru, V., Ionescu, R. T., & Shah, M. (2023) · IEEE Transactions on Pattern Analysis and Machine Intelligence · doi:10.1109/tpami.2023.3261988 · Cited by 1,859 · cited 2×
“…potential to implement more complex DTs in clinical trials, such as diffusion models, which are state-of-the-art in image generation (Figure 3e) [36]; neural ordinary differential equations, which enable learning of continuous dynamic systems (ODEs; Figure 3f) [38] and transformers, which have…”
BackgroundscGPT: Towards Building a Foundation Model for Single-Cell Multi-omics Using Generative AI
Cui, H., Wang, C., Maan, H., Pang, K., Luo, F., & Wang, B. (2023) · doi:10.1101/2023.04.30.538439 · Cited by 1,694
Estimation of clinical trial success rates and related parameters
Wong, C. H., Siah, K. W., & Lo, A. W. (2019) · Biostatistics · doi:10.1093/biostatistics/kxx069 · Cited by 1,585 · cited 1×
“A motivation for DTs in clinical settings is that only one out of ten compounds entering clinical trials will achieve regulatory approval [54].”
BackgroundDeep learning for computational biology
Angermueller, C., Pärnamaa, T., Parts, L., & Stegle, O. (2016) · Molecular Systems Biology · doi:10.15252/msb.20156651 · Cited by 1,473 · cited 1×
“Secondly, most methods rely on less than five thousand patients for training, which is considered small for deep learning [58], and thus may reduce the generalizability of the models.”
MethodLin, T., Wang, Y., Liu, X., & Qiu, X. (2022) · AI Open · doi:10.1016/j.aiopen.2022.10.001 · Cited by 1,422
Research works printed but not linked: 3
- How digital twins of human cells are accelerating drug discovery [internet] DeepLife. 2022 Jun cited 2023 Sep 18. Available from https://www.nature.com/articles/d43747-022-00108-3
- Murphy KP. Probabilistic machine learning: an introduction. Cambridge, Massachusetts: MIT press. 2022 Mar 1.
- Chen RT Rubanova Y Bettencourt J et al. Neural ordinary differential equations. In Proceedings of the 32nd International Conference on Neural Information Processing Systems (NIPS'18); Red Hook NY USA. Curran Associates Inc; 2018. p. 6572–6583. https://proceedings.neurips.cc/paper_files/paper/2018/hash/69386f6bb1dfed68692a24c8686939b9-Abstract.html
Cited by
Bias in medical AI: Implications for clinical decision-making
Cross, J. L., Choma, M. A., & Onofrey, J. A. (2024) · PLOS Digital Health · doi:10.1371/journal.pdig.0000651 · Cited by 607
Ocana, A., Pandiella, A., Privat, C., Bravo, I., Luengo-Oroz, M., Amir, E., & Gyorffy, B. (2025) · Biomarker Research · doi:10.1186/s40364-025-00758-2 · Cited by 187
“The creation of digital replicas of patients allows for the testing of treatments in a virtual environment before actual application, reducing risks and optimizing therapeutic strategies [93, 94].”
Resnik, D. B., & Hosseini, M. (2025) · AI and Ethics · doi:10.1007/s43681-024-00493-8 · Cited by 228
“Also, because synthetic data are similar to but not the same as real data, they can be used to eliminate or mask personal identifiers and protect the confidentiality of human participants [31, 81, 200].”
Islam, M. T., Sepanloo, K., Woo, S., Woo, S. H., & Son, Y. (2025) · Machines · doi:10.3390/machines13040267 · Cited by 222
“Some researchers also highlighted the potential of 6G to integrate AI-driven “semantic communications”, which will ensure that only contextually meaningful information is transmitted [139].”
Generative-AI-Driven Human Digital Twin in IoT Healthcare: A Comprehensive Survey
Chen, J., Shi, Y., Yi, C., Du, H., Kang, J., & Niyato, D. T. (2024) · IEEE Internet of Things Journal · doi:10.1109/jiot.2024.3421918 · Cited by 198
“Standardized application programming interfaces (APIs) and Web services is a practical solution to these challenges.”
BackgroundMethod
Metadata
- Authors
- Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P.
- Affiliations
- Helmholtz Munich (DE)
- Data & Analytics, Pharmaceutical Research and Early Development, Roche Innovation Center Basel (RICB), Basel, Switzerland
- Data & Analytics, Pharmaceutical Research and Early Development, Roche Innovation Center Munich (RICM), Penzberg, Germany
- The University of Melbourne (AU)
- Corresponding author
- Schmich, Fabian
- Menden, Michael P.
- Venue
- Expert Opinion on Drug Discovery
- Publisher
- Informa UK Limited
- Published
- 2023-10-27
- Volume
- 19
- Issue
- 1
- Pages
- 33-42
- ISSN
- 1746-0441 (ISSN-L)
- 1746-045X
- OpenAlex
- W4387966880
- Cited by
- 235
- References
- 57
- Citations by year
- 2026: 82 · 2025: 104 · 2024: 49
- FWCI
- 3.99
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Expert Opinion on Drug Discovery (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Funders
- European Union’s Horizon 2020 Research and Innovation Programme
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Health Sciences › Medicine › Health Informatics › Artificial Intelligence in Healthcare and Education
- Physical Sciences › Computer Science › Artificial Intelligence › Machine Learning in Healthcare
- Keywords
- digital twin, generative AI, drug discovery, clinical trials, in silico modeling, precision medicine, biomarker discovery, regulatory challenges, deep learning
- MeSH terms
- Drug Development, Artificial Intelligence, Clinical Trials as Topic, Computer Simulation, Humans, Biomedical Research, Drug Discovery
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. https://app.cochat.ai/papers/10.1080/17460441.2023.2273839
- The paper
- Bordukova, M., Makarov, N., Rodriguez-Esteban, R., Schmich, F., & Menden, M. P. (2024). Generative artificial intelligence empowers digital twins in drug discovery and clinical trials. Expert Opinion on Drug Discovery. https://doi.org/10.1080/17460441.2023.2273839
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.